What should be included in the management plan for a patient with fatty liver due to metabolic dysfunction (MASH)?

Management Plan for Fatty Liver Due to MASH

The management plan for MASH should prioritize intensive lifestyle modification targeting ≥7-10% weight loss, aggressive treatment of cardiometabolic comorbidities, and consideration of resmetirom or semaglutide for patients with significant fibrosis (stage ≥F2). 1

Core Components of the Management Plan

1. Lifestyle Interventions (Foundation for All Patients)

Weight Loss Targets:

• ≥7-10% body weight reduction for MASH resolution and fibrosis improvement 1
• Minimum 5% weight loss for steatosis reduction 1
• For patients with normal weight, target 3-5% reduction with adapted approach 1

Dietary Modifications:

• Mediterranean diet as the preferred pattern 1
• Minimize processed meat, ultra-processed foods, and sugar-sweetened beverages 1
• Tailor to individual preferences and economic constraints 1

Physical Activity:

• >150 minutes/week of moderate-intensity OR 75 minutes/week of vigorous-intensity exercise 1
• Combine with resistance training to prevent sarcopenia 1

Alcohol:

• Discourage all alcohol consumption 1
• Mandatory avoidance in advanced fibrosis or cirrhosis 1

2. Fibrosis Assessment and Risk Stratification

Initial Assessment:

• Use FIB-4 index as first-line blood-based screening tool 1, 2
• If FIB-4 elevated or indeterminate, proceed to vibration-controlled transient elastography (VCTE) or MR elastography (MRE) 1, 2

Thresholds for Significant Fibrosis (F2-F3):

• VCTE: 8-15 kPa 3
• MRE: 3.1-4.4 kPa 3
• ELF score: 9.2-10.5 3

Cirrhosis Indicators (requiring different management):

• VCTE >20 kPa, MRE >5.0 kPa, ELF >11.3 3
• Platelet count <150,000/mm³ 3
• Imaging showing nodular liver contour or portal hypertension 3

3. Pharmacological Treatment

For Non-Cirrhotic MASH with F2-F3 Fibrosis:

Resmetirom (if locally approved):

• FDA-approved for MASH with significant fibrosis (stage ≥F2) 1
• Demonstrated histological effectiveness on steatohepatitis and fibrosis 1
• Not recommended for cirrhotic stage 1

Semaglutide 2.4 mg/week subcutaneous (Wegovy®):

• FDA-approved for MASH with F2-F3 fibrosis 3, 4
• Achieved MASH resolution in 62.9% vs 34.3% placebo 3
• Achieved ≥1 stage fibrosis reduction in 36.8% vs 22.4% placebo 3
• Do not use in patients with cirrhosis unless already prescribed for another indication 3

GLP-1 Receptor Agonists for Comorbidities:

• Use semaglutide or tirzepatide for patients with type 2 diabetes or obesity with additional metabolic risk factors 1
• Provides dual benefit for metabolic control and liver disease 5

4. Management of Cardiometabolic Comorbidities

This is critical as cardiovascular disease is the leading cause of death in MASH patients 4

Type 2 Diabetes:

• Prioritize incretin-based therapies (GLP-1 agonists, GIP/GLP-1 agonists) 1
• These provide hepatoprotective effects beyond glycemic control 5

Dyslipidemia:

• Statins are safe and reduce cardiovascular events 1
• May contribute to reduction in liver-related events 1

Hypertension:

• Renin-angiotensin-aldosterone modulators may modify disease progression 1

Aspirin:

• Consider for cardiovascular risk reduction 1

5. Bariatric Surgery Consideration

• Indicated for patients with MASH and BMI >35 (or >30 with Asian ethnicity) 1
• Highly effective for MASH resolution and fibrosis improvement 6
• Requires careful patient selection and multidisciplinary evaluation

6. Monitoring Strategy

Non-Invasive Test Monitoring:

• Repeat FIB-4 and elastography at tailored intervals (typically annually) 1
• Treatment response indicators at 72 weeks:
  • ALT reduction >17 U/L or ≥20% 3
  • CAP reduction ≥30% 3
  • VCTE LSM reduction ≥30% 3
  • MRE LSM reduction ≥20% 3

Hepatocellular Carcinoma Surveillance:

• Mandatory for all patients with cirrhosis: ultrasound ± AFP every 6 months 1

Portal Hypertension Surveillance:

• Esophagogastroduodenoscopy for varices screening in cirrhotic patients 1

7. Multidisciplinary Care Model

Essential team members:

• Hepatologist/gastroenterologist for advanced disease 1
• Endocrinologist for diabetes/metabolic management
• Dietician for nutritional counseling 1
• Behavioral therapist for lifestyle modification support 1
• Physiotherapist for exercise prescription 1

A multidisciplinary approach is strongly recommended to target all cardiometabolic components and improve both liver-related and extrahepatic outcomes 1

8. Special Considerations for Cirrhotic Patients

Nutritional Management:

• High-protein diet to prevent sarcopenia 1
• Late-evening snack for compensated cirrhosis 1
• If decompensated: specialized nutritional counseling 1

Metabolic Drug Adaptations:

• Adjust doses based on hepatic function 1
• Avoid metformin in decompensated cirrhosis

Liver Transplantation:

• Evaluate for transplant listing if decompensation occurs 1

Critical Pitfalls to Avoid

1. Do not use liver biopsy for routine monitoring - it's invasive and has sampling limitations 1
2. Do not prescribe resmetirom or semaglutide for cirrhotic MASH - no safety/efficacy data 1, 3
3. Do not ignore cardiovascular risk - it's the #1 cause of death, not liver disease 4
4. Do not delay fibrosis assessment - advanced fibrosis is the key prognostic factor 2
5. Do not recommend alcohol in any amount - even moderate consumption accelerates fibrosis 1